Phase-3 trials to begin on two-dose regimen

In a meeting held last month, the Subject Expert Committee (SEC), which advises the drug regulator-granted permission to the company for conducting Phase III trials on its vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2YhPcF6
via IFTTT